1. AB0472 Pharmacodynamic effect and safety of single-dose sarilumab sc or tocilizumab iv or sc in patients with rheumatoid arthritis (RA). (12th June 2018) Authors: Ishii, T.; Sato, Y.; Munakata, Y.; Kajiwara, M.; Takahashi, Y.; Anwar, F.; Paccaly, A.; Kovalenko, P.; Parrino, J.; Boyapati, A.; Xu, C. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) Authors: Zonder, J. A.; Richter, J.; Bumma, N.; Brayer, J.; Hoffman, J. E.; Bensinger, W. I.; Wu, K. L.; Xu, L.; Chokshi, D.; Boyapati, A.; Cronier, D.; Houvras, Y.; Rodriguez Lorenc, K.; Kroog, G. S.; Dhodapkar, M. V.; Lentzsch, S.; Cooper, D.; Jagannath, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0275 IL-6 Receptor (IL-6R) Blockade with Sarilumab Reduced Circulating Markers Related to Synovial Inflammation and Structural Damage in Patients with Rheumatoid Arthritis (RA) in A Phase 2 Study. (10th June 2014) Authors: Fiore, S.; Boyapati, A.; Hamon, S.C.; van Adelsberg, J.; Liu, M.; Hamilton, J.D. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 278 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗